Comparisons of efficacy and complications between transrectal and transperineal prostate biopsy with or without antibiotic prophylaxis

•TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred•We need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance•Future studies on this topic with improved q...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologic oncology 2022-05, Vol.40 (5), p.191.e9-191.e14
Hauptverfasser: He, Junwei, Guo, Zhenlang, Huang, Yanqin, Wang, Zhaohui, Huang, Lijuan, Li, Baimou, Bai, Zunguang, Wang, Shusheng, Xiang, Songtao, Gu, Chiming, Pan, Jun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 191.e14
container_issue 5
container_start_page 191.e9
container_title Urologic oncology
container_volume 40
creator He, Junwei
Guo, Zhenlang
Huang, Yanqin
Wang, Zhaohui
Huang, Lijuan
Li, Baimou
Bai, Zunguang
Wang, Shusheng
Xiang, Songtao
Gu, Chiming
Pan, Jun
description •TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred•We need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance•Future studies on this topic with improved quality and increased sample size are still needed to minimise bacterial resistance We aimed to determine the cancer detection rate and complications of transrectal prostate biopsy (TRBx) and transperineal prostate biopsy (TPBx) in the hospital. However, given the use of antibiotic prophylaxis in TPBx remains controversial according to the current guidelines, we also investigated the safety and side effects of TPBx with and without antibiotic prophylaxis. A total of 777 patients who underwent prostate biopsy were enrolled in this study in accordance with the criteria. The primary outcome was pooled infectious complications (sepsis, fever, symptomatic urinary tract infection and urinary retention), and the secondary outcome was prostate cancer detection rate. Findings showed that TPBx and TRBx were equivalent in terms of prostate cancer detection rate (TPBx: 50.4% vs. TRBx: 47.3%; P = 0.424) and urinary retention (TPBx: 5% vs. TRBx: 6.3%; P = 0.451). However, TRBx had significantly higher incidences of sepsis (risk ratios, RR: 3.65, 95% confidence interval [CI]: 1.21–11.03; P = 0.014) and symptomatic urinary tract infection (RR: 3.04, 95% CI: 1.07–8.66; P = 0.029) than TPBx. Notably, for TPBx, patients who received a single dose of cephazolin prophylaxis were not associated with the risk of sepsis (RR: 0.78, 95% CI: 0.13–4.63; P = 0.783) and symptomatic urinary tract infection (RR: 1.17, 95% CI: 0.24–5.74; P = 0.848) in contrast to patients who did not receive any antibiotic prophylaxis. Meanwhile, no effects on prostate cancer detection rate and urinary retention were observed in the TPBx group. Our findings indicated that TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred. Importantly, we need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance. This result complements the current national guidelines. Nevertheless, future studies on this topic with improved quality and increased sample size are still needed to minimise bacterial resistance.
doi_str_mv 10.1016/j.urolonc.2022.01.004
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2629379491</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143922000047</els_id><sourcerecordid>2629379491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-2d189692f0c840141b276c108cd7f8c675b05e9b8cab4956c28f078ed0a6207a3</originalsourceid><addsrcrecordid>eNqFUUFu2zAQJIoEdeL0CS10zEUqSUkUeSoKI2kDBMglORPUagXTkEWVpJr6A3l3KNvttaflcmd2MTOEfGa0YJSJr7ti9m5wIxSccl5QVlBafSBXTDZlzislLtKbNjJnValW5DqEHaWskox9JKuyZkJKya_I28btJ-NtcGPIXJ9h31swcMjM2GWQZkNqo12mLcZXxDGL3ozBI0QzHFHHfkJvR0w_k3chmohZa90UDtmrjdvM-WN1c0yMaNMoWlig0_YwmD823JDL3gwBP53rmrzc3z1vfuaPTz8eNt8fcyhFHXPeMamE4j0FWSU1rOWNAEYldE0vQTR1S2tUrQTTVqoWwGWfPMCOGsFpY8o1uT3tTbd_zRii3tsAOAxmRDcHzQVXZaMqxRK0PkEhKUp6ez15uzf-oBnVSwR6p88R6CUCTZlOESTel_OJud1j94_11_ME-HYCYBL626LXASyOgJ1dXNWds_858Q5mDp52</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2629379491</pqid></control><display><type>article</type><title>Comparisons of efficacy and complications between transrectal and transperineal prostate biopsy with or without antibiotic prophylaxis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>He, Junwei ; Guo, Zhenlang ; Huang, Yanqin ; Wang, Zhaohui ; Huang, Lijuan ; Li, Baimou ; Bai, Zunguang ; Wang, Shusheng ; Xiang, Songtao ; Gu, Chiming ; Pan, Jun</creator><creatorcontrib>He, Junwei ; Guo, Zhenlang ; Huang, Yanqin ; Wang, Zhaohui ; Huang, Lijuan ; Li, Baimou ; Bai, Zunguang ; Wang, Shusheng ; Xiang, Songtao ; Gu, Chiming ; Pan, Jun</creatorcontrib><description>•TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred•We need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance•Future studies on this topic with improved quality and increased sample size are still needed to minimise bacterial resistance We aimed to determine the cancer detection rate and complications of transrectal prostate biopsy (TRBx) and transperineal prostate biopsy (TPBx) in the hospital. However, given the use of antibiotic prophylaxis in TPBx remains controversial according to the current guidelines, we also investigated the safety and side effects of TPBx with and without antibiotic prophylaxis. A total of 777 patients who underwent prostate biopsy were enrolled in this study in accordance with the criteria. The primary outcome was pooled infectious complications (sepsis, fever, symptomatic urinary tract infection and urinary retention), and the secondary outcome was prostate cancer detection rate. Findings showed that TPBx and TRBx were equivalent in terms of prostate cancer detection rate (TPBx: 50.4% vs. TRBx: 47.3%; P = 0.424) and urinary retention (TPBx: 5% vs. TRBx: 6.3%; P = 0.451). However, TRBx had significantly higher incidences of sepsis (risk ratios, RR: 3.65, 95% confidence interval [CI]: 1.21–11.03; P = 0.014) and symptomatic urinary tract infection (RR: 3.04, 95% CI: 1.07–8.66; P = 0.029) than TPBx. Notably, for TPBx, patients who received a single dose of cephazolin prophylaxis were not associated with the risk of sepsis (RR: 0.78, 95% CI: 0.13–4.63; P = 0.783) and symptomatic urinary tract infection (RR: 1.17, 95% CI: 0.24–5.74; P = 0.848) in contrast to patients who did not receive any antibiotic prophylaxis. Meanwhile, no effects on prostate cancer detection rate and urinary retention were observed in the TPBx group. Our findings indicated that TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred. Importantly, we need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance. This result complements the current national guidelines. Nevertheless, future studies on this topic with improved quality and increased sample size are still needed to minimise bacterial resistance.</description><identifier>ISSN: 1078-1439</identifier><identifier>ISSN: 1873-2496</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2022.01.004</identifier><identifier>PMID: 35168882</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Antibiotic Prophylaxis ; Biopsy - adverse effects ; Complications ; Efficacy ; Humans ; Image-Guided Biopsy ; Male ; Prostate - pathology ; Prostatic Neoplasms - pathology ; Sepsis ; Transperineal prostate biopsy ; Transrectal prostate biopsy ; Urinary Retention - etiology ; Urinary Retention - prevention &amp; control ; Urinary Tract Infections - etiology ; Urinary Tract Infections - prevention &amp; control</subject><ispartof>Urologic oncology, 2022-05, Vol.40 (5), p.191.e9-191.e14</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-2d189692f0c840141b276c108cd7f8c675b05e9b8cab4956c28f078ed0a6207a3</citedby><cites>FETCH-LOGICAL-c365t-2d189692f0c840141b276c108cd7f8c675b05e9b8cab4956c28f078ed0a6207a3</cites><orcidid>0000-0002-3309-7182</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1078143922000047$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35168882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Junwei</creatorcontrib><creatorcontrib>Guo, Zhenlang</creatorcontrib><creatorcontrib>Huang, Yanqin</creatorcontrib><creatorcontrib>Wang, Zhaohui</creatorcontrib><creatorcontrib>Huang, Lijuan</creatorcontrib><creatorcontrib>Li, Baimou</creatorcontrib><creatorcontrib>Bai, Zunguang</creatorcontrib><creatorcontrib>Wang, Shusheng</creatorcontrib><creatorcontrib>Xiang, Songtao</creatorcontrib><creatorcontrib>Gu, Chiming</creatorcontrib><creatorcontrib>Pan, Jun</creatorcontrib><title>Comparisons of efficacy and complications between transrectal and transperineal prostate biopsy with or without antibiotic prophylaxis</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>•TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred•We need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance•Future studies on this topic with improved quality and increased sample size are still needed to minimise bacterial resistance We aimed to determine the cancer detection rate and complications of transrectal prostate biopsy (TRBx) and transperineal prostate biopsy (TPBx) in the hospital. However, given the use of antibiotic prophylaxis in TPBx remains controversial according to the current guidelines, we also investigated the safety and side effects of TPBx with and without antibiotic prophylaxis. A total of 777 patients who underwent prostate biopsy were enrolled in this study in accordance with the criteria. The primary outcome was pooled infectious complications (sepsis, fever, symptomatic urinary tract infection and urinary retention), and the secondary outcome was prostate cancer detection rate. Findings showed that TPBx and TRBx were equivalent in terms of prostate cancer detection rate (TPBx: 50.4% vs. TRBx: 47.3%; P = 0.424) and urinary retention (TPBx: 5% vs. TRBx: 6.3%; P = 0.451). However, TRBx had significantly higher incidences of sepsis (risk ratios, RR: 3.65, 95% confidence interval [CI]: 1.21–11.03; P = 0.014) and symptomatic urinary tract infection (RR: 3.04, 95% CI: 1.07–8.66; P = 0.029) than TPBx. Notably, for TPBx, patients who received a single dose of cephazolin prophylaxis were not associated with the risk of sepsis (RR: 0.78, 95% CI: 0.13–4.63; P = 0.783) and symptomatic urinary tract infection (RR: 1.17, 95% CI: 0.24–5.74; P = 0.848) in contrast to patients who did not receive any antibiotic prophylaxis. Meanwhile, no effects on prostate cancer detection rate and urinary retention were observed in the TPBx group. Our findings indicated that TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred. Importantly, we need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance. This result complements the current national guidelines. Nevertheless, future studies on this topic with improved quality and increased sample size are still needed to minimise bacterial resistance.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotic Prophylaxis</subject><subject>Biopsy - adverse effects</subject><subject>Complications</subject><subject>Efficacy</subject><subject>Humans</subject><subject>Image-Guided Biopsy</subject><subject>Male</subject><subject>Prostate - pathology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Sepsis</subject><subject>Transperineal prostate biopsy</subject><subject>Transrectal prostate biopsy</subject><subject>Urinary Retention - etiology</subject><subject>Urinary Retention - prevention &amp; control</subject><subject>Urinary Tract Infections - etiology</subject><subject>Urinary Tract Infections - prevention &amp; control</subject><issn>1078-1439</issn><issn>1873-2496</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUUFu2zAQJIoEdeL0CS10zEUqSUkUeSoKI2kDBMglORPUagXTkEWVpJr6A3l3KNvttaflcmd2MTOEfGa0YJSJr7ti9m5wIxSccl5QVlBafSBXTDZlzislLtKbNjJnValW5DqEHaWskox9JKuyZkJKya_I28btJ-NtcGPIXJ9h31swcMjM2GWQZkNqo12mLcZXxDGL3ozBI0QzHFHHfkJvR0w_k3chmohZa90UDtmrjdvM-WN1c0yMaNMoWlig0_YwmD823JDL3gwBP53rmrzc3z1vfuaPTz8eNt8fcyhFHXPeMamE4j0FWSU1rOWNAEYldE0vQTR1S2tUrQTTVqoWwGWfPMCOGsFpY8o1uT3tTbd_zRii3tsAOAxmRDcHzQVXZaMqxRK0PkEhKUp6ez15uzf-oBnVSwR6p88R6CUCTZlOESTel_OJud1j94_11_ME-HYCYBL626LXASyOgJ1dXNWds_858Q5mDp52</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>He, Junwei</creator><creator>Guo, Zhenlang</creator><creator>Huang, Yanqin</creator><creator>Wang, Zhaohui</creator><creator>Huang, Lijuan</creator><creator>Li, Baimou</creator><creator>Bai, Zunguang</creator><creator>Wang, Shusheng</creator><creator>Xiang, Songtao</creator><creator>Gu, Chiming</creator><creator>Pan, Jun</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3309-7182</orcidid></search><sort><creationdate>20220501</creationdate><title>Comparisons of efficacy and complications between transrectal and transperineal prostate biopsy with or without antibiotic prophylaxis</title><author>He, Junwei ; Guo, Zhenlang ; Huang, Yanqin ; Wang, Zhaohui ; Huang, Lijuan ; Li, Baimou ; Bai, Zunguang ; Wang, Shusheng ; Xiang, Songtao ; Gu, Chiming ; Pan, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-2d189692f0c840141b276c108cd7f8c675b05e9b8cab4956c28f078ed0a6207a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotic Prophylaxis</topic><topic>Biopsy - adverse effects</topic><topic>Complications</topic><topic>Efficacy</topic><topic>Humans</topic><topic>Image-Guided Biopsy</topic><topic>Male</topic><topic>Prostate - pathology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Sepsis</topic><topic>Transperineal prostate biopsy</topic><topic>Transrectal prostate biopsy</topic><topic>Urinary Retention - etiology</topic><topic>Urinary Retention - prevention &amp; control</topic><topic>Urinary Tract Infections - etiology</topic><topic>Urinary Tract Infections - prevention &amp; control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Junwei</creatorcontrib><creatorcontrib>Guo, Zhenlang</creatorcontrib><creatorcontrib>Huang, Yanqin</creatorcontrib><creatorcontrib>Wang, Zhaohui</creatorcontrib><creatorcontrib>Huang, Lijuan</creatorcontrib><creatorcontrib>Li, Baimou</creatorcontrib><creatorcontrib>Bai, Zunguang</creatorcontrib><creatorcontrib>Wang, Shusheng</creatorcontrib><creatorcontrib>Xiang, Songtao</creatorcontrib><creatorcontrib>Gu, Chiming</creatorcontrib><creatorcontrib>Pan, Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Junwei</au><au>Guo, Zhenlang</au><au>Huang, Yanqin</au><au>Wang, Zhaohui</au><au>Huang, Lijuan</au><au>Li, Baimou</au><au>Bai, Zunguang</au><au>Wang, Shusheng</au><au>Xiang, Songtao</au><au>Gu, Chiming</au><au>Pan, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparisons of efficacy and complications between transrectal and transperineal prostate biopsy with or without antibiotic prophylaxis</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>40</volume><issue>5</issue><spage>191.e9</spage><epage>191.e14</epage><pages>191.e9-191.e14</pages><issn>1078-1439</issn><issn>1873-2496</issn><eissn>1873-2496</eissn><abstract>•TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred•We need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance•Future studies on this topic with improved quality and increased sample size are still needed to minimise bacterial resistance We aimed to determine the cancer detection rate and complications of transrectal prostate biopsy (TRBx) and transperineal prostate biopsy (TPBx) in the hospital. However, given the use of antibiotic prophylaxis in TPBx remains controversial according to the current guidelines, we also investigated the safety and side effects of TPBx with and without antibiotic prophylaxis. A total of 777 patients who underwent prostate biopsy were enrolled in this study in accordance with the criteria. The primary outcome was pooled infectious complications (sepsis, fever, symptomatic urinary tract infection and urinary retention), and the secondary outcome was prostate cancer detection rate. Findings showed that TPBx and TRBx were equivalent in terms of prostate cancer detection rate (TPBx: 50.4% vs. TRBx: 47.3%; P = 0.424) and urinary retention (TPBx: 5% vs. TRBx: 6.3%; P = 0.451). However, TRBx had significantly higher incidences of sepsis (risk ratios, RR: 3.65, 95% confidence interval [CI]: 1.21–11.03; P = 0.014) and symptomatic urinary tract infection (RR: 3.04, 95% CI: 1.07–8.66; P = 0.029) than TPBx. Notably, for TPBx, patients who received a single dose of cephazolin prophylaxis were not associated with the risk of sepsis (RR: 0.78, 95% CI: 0.13–4.63; P = 0.783) and symptomatic urinary tract infection (RR: 1.17, 95% CI: 0.24–5.74; P = 0.848) in contrast to patients who did not receive any antibiotic prophylaxis. Meanwhile, no effects on prostate cancer detection rate and urinary retention were observed in the TPBx group. Our findings indicated that TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred. Importantly, we need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance. This result complements the current national guidelines. Nevertheless, future studies on this topic with improved quality and increased sample size are still needed to minimise bacterial resistance.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35168882</pmid><doi>10.1016/j.urolonc.2022.01.004</doi><orcidid>https://orcid.org/0000-0002-3309-7182</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1078-1439
ispartof Urologic oncology, 2022-05, Vol.40 (5), p.191.e9-191.e14
issn 1078-1439
1873-2496
1873-2496
language eng
recordid cdi_proquest_miscellaneous_2629379491
source MEDLINE; Elsevier ScienceDirect Journals
subjects Anti-Bacterial Agents - therapeutic use
Antibiotic Prophylaxis
Biopsy - adverse effects
Complications
Efficacy
Humans
Image-Guided Biopsy
Male
Prostate - pathology
Prostatic Neoplasms - pathology
Sepsis
Transperineal prostate biopsy
Transrectal prostate biopsy
Urinary Retention - etiology
Urinary Retention - prevention & control
Urinary Tract Infections - etiology
Urinary Tract Infections - prevention & control
title Comparisons of efficacy and complications between transrectal and transperineal prostate biopsy with or without antibiotic prophylaxis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A47%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparisons%20of%20efficacy%20and%20complications%20between%20transrectal%20and%20transperineal%20prostate%20biopsy%20with%20or%20without%20antibiotic%20prophylaxis&rft.jtitle=Urologic%20oncology&rft.au=He,%20Junwei&rft.date=2022-05-01&rft.volume=40&rft.issue=5&rft.spage=191.e9&rft.epage=191.e14&rft.pages=191.e9-191.e14&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2022.01.004&rft_dat=%3Cproquest_cross%3E2629379491%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2629379491&rft_id=info:pmid/35168882&rft_els_id=S1078143922000047&rfr_iscdi=true